Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC18A3 | Q16572 | 10/20 | 0.54 |
| ▸ | DRD2 | P14416 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | APEX1 | P27695 | 1/20 | 0.46 |
| ▸ | BLM | P54132 | 1/20 | 0.46 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.46 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.46 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.45 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14112100 | 0.85 | SLC18A3 (0.53) | SLC18A3CYP2D6TSHRSMN1; SMN2CYP1A2 | |
| SCHEMBL15502340 | 0.82 | SLC18A3 (0.50) | SLC18A3DRD2 | |
| SCHEMBL15581594 | 0.82 | DRD2 (0.58) | DRD2SIGMAR1 | |
| SCHEMBL13225909 | 0.80 | DRD2 (0.40) | SLC18A3DRD2SIGMAR1ALDH1A1 | |
| SCHEMBL13406302 | 0.80 | CYP11B2 (0.54) | ALDH1A1 | |
| SCHEMBL14252408 | 0.74 | SLC18A3 (0.55) | SLC18A3DRD2CYP2D6TSHRSMN1; SMN2 | |
| SCHEMBL54932 | 0.74 | DRD2 (0.63) | SLC18A3DRD2CYP2D6TSHRCYP1A2 | |
| SCHEMBL1477625 | 0.74 | SLC18A3 (0.58) | SLC18A3DRD2CYP2D6TSHRSMN1; SMN2 | |
| SCHEMBL13210996 | 0.74 | RAB9A (0.35) | SLC18A3DRD2TSHRSMN1; SMN2ALDH1A1 | |
| SCHEMBL10201928 | 0.73 | TRPC6 (0.43) | SLC18A3DRD2SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7700778-B2 | Acylated piperidine derivatives as melanocortin-4 receptor agonists | MERCK SHARP & DOHME CORP. (US) | 2010-04-20 | — | — | US | disclosed |
| US-20070043080-A1 | Substituted anilinic piperidines as MCH selective antagonists | MARZABADI MOHAMMAD R | 2007-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070043080-A1 | Substituted anilinic piperidines as MCH selective antagonists | MCHR1, MCHR2, MC1R | SLC18A3 284/4885DRD2 119/4885CYP2D6 885/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.